Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists track rare ataxia to unlock future treatments

NCT ID NCT05177809

Knowledge-focused Sponsor: Prof. Dr. Matthis Synofzik Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 150 adults with RFC1-related ataxia (a balance and coordination disorder) over two years. Researchers will measure symptoms, perform imaging, and test blood samples to understand how the disease progresses. The goal is to find markers that can help diagnose the condition and measure treatment effects in future clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study enrolls probands with clinically manifest and genetically confirmed RFC1 repeat expansion disease, as well as healthy unrelated controls to contrast unspecific, age- or sex-related findings to disease-related specific findings.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * RFC1: genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1 * Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND * Written informed consent AND * Participants are willing and able to comply with study procedures Exclusion Criteria: * RFC1: Missing informed consent * Controls: evidence of neuropathy, neurodegenerative disease, or movement disorder; inability to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ataxia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ataxia cerebellar ataxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ataxia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Neurology & Hertie-Institute for Clinical Brain Research, Dept. for Neurodegenerative Diseases

    RECRUITING

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Centre of Brain Research Neurogenetics Research Clinic, University of Auckland

    RECRUITING

    Auckland, 1142, New Zealand

  • Department of Neurology University Hospital Schleswig Holstein

    RECRUITING

    Lübeck, Schleswig-Holstein, 23562, Germany

  • Department of Neurology, Ataxia Unit, Universidade Federal de São Paulo

    RECRUITING

    São Paulo, State of São Paulo, 04040-003, Brazil

  • Department of Neuroscience, Central Clinical School, Monash University

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • German Center for Neurodegenerative Diseases (DZNE)

    RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

  • IRCCS Fondazione Stella Maris

    RECRUITING

    Pisa, 56128, Italy

  • Koç University Hospital, KUTTAM-NDAL

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • Service de Neurologie, Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, Strasbourg, 67000, France

  • Università degli Studi di Napoli 'Federico II', c/o AOU Federico II

    RECRUITING

    Naples, Napoli, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.